141080 - LigaChem Biosciences Inc.

141080 Summary

Biopharma

Stock Price & Overview

₩92,000 +3,700 (+4.19%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩92,000 ≈ US$66 · Market cap ₩3.4tn (≈ $2.4bn)

141080 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	141.6	125.9	34.1	33.4	32.2	49.4	57.5	25.2	22.1	16.7	1.8
Cost of Revenue	15.6	15.9	16.3	15.6	14.5	13.8	22.7	19.3	15.3	12.5	0.7
Selling, General & Administrative	16.4	21.1	14.0	—	—	—	—	—	—	—	—
Operating Income	-106.5	-20.9	-80.8	-50.4	-27.7	-29.8	8.4	-16.0	-9.8	-10.2	-8.0
Finance Income	4.2	14.2	7.5	6.0	3.2	21.0	5.7	1.1	0.5	0.4	0.5
Finance Costs	11.3	5.1	9.1	7.8	0.9	3.4	0.8	0.1	1.4	1.1	0.9
Pretax Income	-93.9	9.1	-75.7	-47.7	-20.5	-8.8	13.1	-26.4	-13.5	-15.4	-8.4
Income Tax Expense	-2.3	1.3	-2.0	2.6	-2.9	1.8	0.6	-0.4	-0.6	-0.6	-0.2
Net Income	-91.6	7.8	-73.7	-45.1	-23.4	-7.0	12.5	-26.1	-12.9	-14.7	-8.2
Total Comprehensive Income	-71.4	6.5	-74.2	-45.7	-24.0	-4.2	9.8	-25.8	-12.8	-14.8	-8.2
Interest Income	18.2	19.8	5.7	4.2	0.9	1.0	—	—	—	—	—

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	701.8	738.4	189.5	252.5	293.2	135.9	141.5	121.7	82.2	89.6	68.4
Current Assets	521.4	550.3	134.6	191.6	229.0	100.0	111.4	93.4	45.2	49.6	29.6
Cash & Cash Equivalents	98.6	128.9	63.1	118.0	139.9	54.6	66.9	10.2	8.6	3.0	2.4
Inventories	0.1	0.2	0.2	0.2	0.3	0.3	2.0	0.8	0.9	0.4	0.0
Trade Receivables	11.8	13.7	14.8	12.8	22.5	20.6	11.1	17.7	15.5	12.6	9.2
Non-current Assets	180.4	188.1	54.9	60.9	64.3	35.9	30.1	28.3	37.0	39.9	38.8
Property, Plant & Equipment	27.7	25.3	25.4	26.5	24.4	7.6	12.1	10.3	7.8	6.9	3.5
Intangible Assets	104.5	8.4	6.9	7.9	8.6	8.1	9.0	10.1	22.8	26.8	32.9
Total Liabilities	160.7	122.4	41.3	32.9	34.5	23.8	25.6	16.4	32.8	29.5	25.3
Current Liabilities	61.1	117.2	37.1	28.6	17.0	14.0	15.4	9.9	17.6	15.0	9.2
Non-current Liabilities	99.6	5.2	4.2	4.3	17.4	9.8	10.1	6.4	15.1	14.5	16.1
Total Equity	541.1	616.0	148.2	219.6	258.8	112.1	115.9	105.3	49.5	60.1	43.2
Share Capital	18.3	18.3	14.2	13.8	13.6	12.1	6.0	6.0	5.0	5.0	4.5
Retained Earnings	211.8	36.3	30.7	105.4	-109.6	-86.1	-78.8	-90.3	-64.3	-51.4	-36.7

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	-124.5	78.5	-62.2	-7.1	-42.0	-14.9	24.1	-12.8	-8.2	-13.0	-8.8
Cash from Investing Activities	94.1	-457.4	9.4	-16.2	-43.9	0.3	30.0	-50.6	11.9	-20.2	9.2
Purchase of Property, Plant & Equipment	3.0	2.6	1.3	4.2	18.3	2.7	3.4	3.8	2.2	4.2	0.4
Cash from Financing Activities	-0.6	443.4	-1.9	3.2	171.3	2.6	2.6	64.9	2.0	33.7	0.2
Net Change in Cash	-31.0	64.5	-54.8	-20.1	85.3	-11.9	56.7	1.6	5.7	0.5	0.8

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	5.5	35.9	16.0	41.4	32.6	51.6	33.7	30.4	30.8	31.1
Cost of Revenue	2.4	2.3	3.7	3.8	4.1	4.0	4.3	3.7	4.2	3.8
Selling, General & Administrative	5.7	4.2	3.9	3.6	5.1	3.8	7.4	3.7	6.5	3.5
Operating Income	-72.0	-37.4	-73.1	-23.2	-21.5	11.4	-13.7	0.5	-10.6	2.9
Finance Income	2.4	4.7	1.4	1.0	-8.7	10.5	6.3	3.7	-1.1	5.4
Finance Costs	2.5	5.6	-0.1	-2.3	12.7	1.0	3.0	-1.0	2.3	0.8
Pretax Income	-68.1	-34.3	-66.9	-15.3	-38.1	26.5	-4.7	11.4	-7.3	9.7
Income Tax Expense	0.1	-1.0	-2.3	0.0	-0.0	0.0	-1.9	0.1	-0.1	0.3
Net Income	-68.1	-33.3	-64.6	-15.3	-38.1	26.5	-5.4	11.2	-7.4	9.4
Total Comprehensive Income	-75.2	-41.9	-57.2	-16.1	-24.3	26.2	-5.2	10.9	-7.7	8.4
Interest Income	3.4	3.5	4.1	4.2	4.5	5.4	5.6	6.0	6.1	2.2

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	594.1	652.9	701.8	699.4	703.7	739.8	738.4	727.1	739.3	765.1
Current Assets	426.1	480.0	521.4	595.6	623.4	538.9	550.3	562.3	583.0	707.7
Cash & Cash Equivalents	84.1	63.5	98.6	153.5	136.0	108.4	128.9	153.6	177.0	566.3
Inventories	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.3
Trade Receivables	10.7	10.0	11.8	14.2	34.7	44.1	13.7	11.7	12.3	11.7
Non-current Assets	168.0	173.0	180.4	103.8	80.2	200.9	188.1	164.8	156.3	57.4
Property, Plant & Equipment	28.1	27.1	27.7	27.7	28.3	27.7	25.3	25.6	25.9	25.1
Intangible Assets	105.2	104.6	104.5	39.2	16.0	28.5	8.4	6.9	6.7	6.7
Total Liabilities	153.2	152.4	160.7	136.4	152.2	170.5	122.4	89.8	114.3	137.4
Current Liabilities	45.5	47.4	61.1	66.4	82.4	101.3	117.2	82.5	107.4	131.3
Non-current Liabilities	107.7	105.0	99.6	69.9	69.8	69.1	5.2	7.3	6.9	6.0
Total Equity	441.0	500.5	541.1	563.1	551.5	569.4	616.0	637.3	625.0	627.7
Share Capital	18.5	18.3	18.3	18.3	18.3	18.3	18.3	18.3	18.3	18.2
Retained Earnings	102.0	173.6	211.8	265.9	281.4	311.8	36.3	42.3	31.2	38.9

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-59.5	-46.6	-73.3	-12.2	-8.4	-30.6	14.6	-22.6	-20.1	106.6
Cash from Investing Activities	64.1	9.6	18.0	32.1	30.9	13.1	-11.1	-0.4	-372.6	-73.2
Purchase of Property, Plant & Equipment	1.3	0.3	0.9	0.4	1.4	0.3	0.6	0.8	0.8	0.5
Cash from Financing Activities	14.7	-0.3	-0.8	-1.1	4.3	-3.0	-29.6	-0.1	3.3	469.7
Net Change in Cash	19.3	-37.3	-56.1	18.9	26.8	-20.6	-26.1	-23.2	-389.4	503.2

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

141080 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	141.6	+12.4%	+61.8%	+23.4%	+54.8%
Operating income	-106.5	—	—	—	—
Net income	-91.6	—	—	—	—
EPS	₩-2,473	—	—	—	—
Operating cash flow	-124.5	—	—	—	—
Shareholders' equity	541.1	-12.2%	+35.1%	+37.0%	+28.8%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

141080 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Operating margin	-75.2%	-16.6%	-236.7%	-150.8%	-86.2%	-60.3%
Net margin	-64.7%	6.2%	-215.9%	-135.0%	-72.7%	-14.1%
Return on equity	-15.8%	2.0%	-40.1%	-18.9%	-12.6%	-6.1%
Return on assets	-12.7%	1.7%	-33.3%	-16.5%	-10.9%	-5.0%
Operating cash flow / revenue	-88.0%	62.3%	-182.3%	-21.4%	-130.8%	-30.2%
Capex / revenue	2.2%	2.1%	3.9%	12.5%	56.9%	5.5%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 141080

Symbol	Last Price
028300HLB Co., Ltd.	₩33,750 +2.9%
298380ABL Bio Inc.	₩71,400 +5.6%
000250Samchundang Pharm	₩157,000 +1.0%
087010Peptron, Inc.	₩157,300 +7.3%
145020Hugel, Inc.	₩244,000 +1.5%
302440SK Bioscience Co., Ltd.	₩37,900 +0.4%
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%
310210Voronoi, Inc.	₩153,000 +3.9%
214370Caregen Co., Ltd.	₩44,500 +1.5%
347850D & D Pharmatech, Inc.	₩49,200 +1.4%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.